S81231 |
CNX-774 |
源葉(MedMol) | 98% |
品牌 | 貨號 | 產品規(guī)格 | 價格(RMB) | 庫存(上海) | 北京 | 武漢 | 南京 | 數(shù)量 | 計量單位 | 加入購物車... |
---|---|---|---|---|---|---|---|---|---|---|
源葉(MedMol) | S81231-2mg | 98% | ¥50.00元 | 5 | - | - | - | EA | 加入購物車 | |
源葉(MedMol) | S81231-5mg | 98% | ¥60.00元 | 6 | - | - | - | EA | 加入購物車 | |
源葉(MedMol) | S81231-10mg | 98% | ¥110.00元 | 6 | - | - | - | EA | 加入購物車 | |
源葉(MedMol) | S81231-50mg | 98% | ¥500.00元 | 3 | - | - | - | EA | 加入購物車 |
- 提示:詳情請下載說明書。
- 產品描述: CNX-774 is an orally active, irreversible and selective BTK inhibitor, with an IC50 of < 1 nM. CNX-774 specifically targets Cysteine 481 of Btk for covalent modification
- 靶點: IC50: 1 nM (BTK);BTK
- 體內研究:
CNX-774 is stable and non-reactive in fresh human and rat whole blood and does not covalently bond to any of the mid-level abundance human plasma proteins. CNX-774 demonstrates potent inhibitory activity towards the intended target, Btk, while achieving remarkable specificity in a variety of assays designed to assess off-target reactivity towards abundant cellular thiols and blood proteins
- 參考文獻:
1. Matthew Labenski, et al. In Vitro Reactivity Assessment of Covalent Drugs Targeting Bruton's Tyrosine Kinase. 2. Akintunde Akinleye, et al. Ibrutinib and novel BTK inhibitors in clinical development. J Hematol Oncol. 2013 Aug 19;6:59.
- 溶解性: DMSO : ≥ 45 mg/mL (90.09 mM)
- 保存條件: 2-8℃
- 配置溶液濃度參考:
1mg 5mg 10mg 1 mM 2.002 ml 10.01 ml 20.02 ml 5 mM 0.4 ml 2.002 ml 4.004 ml 10 mM 0.2 ml 1.001 ml 2.002 ml 50 mM 0.04 ml 0.2 ml 0.4 ml
- 注意:部分產品我司僅能提供部分信息,我司不保證所提供信息的權威性,僅供客戶參考交流研究之用。
輸入產品批號:
本計算器可幫助您計算出特定溶液中溶質的質量、溶液濃度和體積之間的關系,公式為:
質量 (mg) = 濃度 (mM) x 體積 (mL) x 分子摩爾量 (g/mol)
=**